PBYI PUMA BIOTECHNOLOGY, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1401667 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.4%
TTM net income YoY-35.6%
TTM EPS YoY-38.7%
Revenue 3-yr CAGR0.4%
Net income 3-yr CAGR85.8%
Margins
Gross margin73.6%
Operating margin11.3%
Net margin10.3%
FCF margin19.9%
EBITDA margin15.7%
Returns
ROE18.2%
ROA11.7%
ROIC (approx.)26.1%
Asset turnover1.14x
Leverage & solvency
Liabilities / assets27.7%
Debt / equity0.00x
Current ratio3.03x
Interest coverage12.88x
Cash quality & payout
Operating cash flow / net income1.93x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue-0.0%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $228.37M | $230.47M | $235.64M | $228.03M | $253.16M |
| Cost of revenue | $58.16M | $64.40M | $62.68M | $55.09M | $63.70M |
| Gross profit | $170.21M | $166.06M | $172.96M | $172.94M | $189.45M |
| R&D expense | $62.07M | $54.94M | $50.38M | $52.24M | $71.87M |
| SG&A expense | $70.85M | $80.16M | $89.93M | $89.98M | $116.29M |
| Operating income | $37.30M | $30.97M | $32.64M | $23.72M | $1.29M |
| Interest expense | $6.62M | $12.45M | $13.33M | $11.59M | $12.81M |
| Pretax income | $35.78M | $24.10M | $22.67M | $457,000 | -$28.80M |
| Income tax | $4.67M | -$6.18M | $1.08M | $455,000 | $324,000 |
| Net income | $31.11M | $30.28M | $21.59M | $2,000 | -$29.13M |
| EBITDA | $48.24M | $42.49M | $44.16M | $33.56M | $12.60M |
| EPS (basic) | 0.62 | 0.62 | 0.46 | 0.00 | -0.72 |
| EPS (diluted) | 0.61 | 0.62 | 0.45 | 0.00 | -0.72 |
| Weighted avg. shares (diluted) | 50.65M | 49.10M | 47.55M | 44.93M | 40.64M |
| Balance sheet | |||||
| Cash & equivalents | $29.64M | $69.22M | $84.58M | $76.20M | $63.13M |
| Short-term investments | $67.89M | $31.75M | $11.35M | $4.87M | $18.98M |
| Receivables | $53.65M | $32.01M | $47.84M | $40.35M | $32.53M |
| Inventory | $5.51M | $8.72M | $7.08M | $4.53M | $7.11M |
| Current assets | $162.69M | $147.66M | $156.19M | $134.28M | $140.02M |
| PP&E, net | $187,000 | $515,000 | $855,000 | $1.15M | $1.76M |
| Intangibles | $41.39M | $51.13M | $60.87M | $70.61M | $66.12M |
| Total assets | $216.30M | $213.33M | $230.53M | $222.06M | $226.59M |
| Current liabilities | $81.25M | $96.11M | $99.38M | $77.48M | $109.59M |
| Short-term debt | $22.52M | $45.33M | $34.00M | $0 | $0 |
| Long-term debt | $0 | $21.72M | $65.66M | $98.31M | $97.09M |
| Total debt | $22.52M | $67.05M | $99.66M | $98.31M | $97.09M |
| Total liabilities | $85.96M | $121.21M | $177.09M | $200.45M | $229.03M |
| Shareholders' equity | $130.34M | $92.12M | $53.44M | $21.61M | -$2.45M |
| Net debt | -$7.11M | -$2.17M | $15.07M | $22.11M | $33.96M |
| Shares outstanding | 50.41M | 49.11M | 47.65M | 46.35M | 41.18M |
| Cash flow statement | |||||
| Operating cash flow | $41.80M | $38.92M | $27.01M | -$15.83M | $20.65M |
| Capital expenditure | $71,000 | $56,000 | $140,000 | $0 | $0 |
| Free cash flow | $41.73M | $38.86M | $26.87M | -$15.83M | $20.65M |
| Investing cash flow | -$36.19M | -$20.44M | -$19.12M | $7.10M | -$10.88M |
| Financing cash flow | -$45.20M | -$33.85M | $0 | $12.22M | -$31.93M |
| Depreciation & amortization | $10.94M | $11.52M | $11.52M | $9.84M | $11.30M |
| Stock-based compensation | $6.94M | $8.24M | $10.25M | $11.83M | $32.63M |
Free plan shows the latest 5 periods; Pro shows all 15 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.